These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
83 related articles for article (PubMed ID: 11834544)
21. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. Lipsky PE; van der Heijde DM; St Clair EW; Furst DE; Breedveld FC; Kalden JR; Smolen JS; Weisman M; Emery P; Feldmann M; Harriman GR; Maini RN; N Engl J Med; 2000 Nov; 343(22):1594-602. PubMed ID: 11096166 [TBL] [Abstract][Full Text] [Related]
22. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. Bathon JM; Martin RW; Fleischmann RM; Tesser JR; Schiff MH; Keystone EC; Genovese MC; Wasko MC; Moreland LW; Weaver AL; Markenson J; Finck BK N Engl J Med; 2000 Nov; 343(22):1586-93. PubMed ID: 11096165 [TBL] [Abstract][Full Text] [Related]
23. Consensus statement on the initiation and continuation of tumour necrosis factor blocking therapies in rheumatoid arthritis. Smolen JS; Breedveld FC; Burmester GR; Combe B; Emery P; Kalden JR; Klareskog L; Maini RN; Numo R; van De Putte LB; van Riel PL; Rodriguez-Valverde V Ann Rheum Dis; 2000 Jul; 59(7):504-5. PubMed ID: 10873957 [No Abstract] [Full Text] [Related]
24. Targeted therapies in rheumatoid arthritis: the need for action. Emery P; Panayi G; Sturrock R; Williams B Rheumatology (Oxford); 1999 Oct; 38(10):911-2. PubMed ID: 10534539 [No Abstract] [Full Text] [Related]
25. IL-1 alpha beta blockade prevents cartilage and bone destruction in murine type II collagen-induced arthritis, whereas TNF-alpha blockade only ameliorates joint inflammation. Joosten LA; Helsen MM; Saxne T; van De Loo FA; Heinegard D; van Den Berg WB J Immunol; 1999 Nov; 163(9):5049-55. PubMed ID: 10528210 [TBL] [Abstract][Full Text] [Related]
27. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Maini RN; Breedveld FC; Kalden JR; Smolen JS; Davis D; Macfarlane JD; Antoni C; Leeb B; Elliott MJ; Woody JN; Schaible TF; Feldmann M Arthritis Rheum; 1998 Sep; 41(9):1552-63. PubMed ID: 9751087 [TBL] [Abstract][Full Text] [Related]
28. Role of cytokines in rheumatoid arthritis. Feldmann M; Brennan FM; Maini RN Annu Rev Immunol; 1996; 14():397-440. PubMed ID: 8717520 [TBL] [Abstract][Full Text] [Related]
29. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Elliott MJ; Maini RN; Feldmann M; Kalden JR; Antoni C; Smolen JS; Leeb B; Breedveld FC; Macfarlane JD; Bijl H Lancet; 1994 Oct; 344(8930):1105-10. PubMed ID: 7934491 [TBL] [Abstract][Full Text] [Related]
30. Worldwide trends in the socioeconomic impact and long-term prognosis of rheumatoid arthritis. Markenson JA Semin Arthritis Rheum; 1991 Oct; 21(2 Suppl 1):4-12. PubMed ID: 1836280 [TBL] [Abstract][Full Text] [Related]
31. Treating rheumatoid arthritis with tumour necrosis factor alpha blockade. Emery P; Buch M BMJ; 2002 Feb; 324(7333):312-3. PubMed ID: 11834544 [No Abstract] [Full Text] [Related]
32. Summary of clinical trials in rheumatoid arthritis using infliximab, an anti-TNFalpha treatment. Harriman G; Harper LK; Schaible TF Ann Rheum Dis; 1999 Nov; 58 Suppl 1(Suppl 1):I61-4. PubMed ID: 10577975 [No Abstract] [Full Text] [Related]
33. Anti-tumour necrosis factor specific antibody (infliximab) treatment provides insights into the pathophysiology of rheumatoid arthritis. Maini RN; Taylor PC; Paleolog E; Charles P; Ballara S; Brennan FM; Feldmann M Ann Rheum Dis; 1999 Nov; 58 Suppl 1(Suppl 1):I56-60. PubMed ID: 10577974 [No Abstract] [Full Text] [Related]
34. Anti-TNF alpha therapy in rheumatoid arthritis--current and future directions. Taylor PC; Williams RO; Maini RN Curr Dir Autoimmun; 2000; 2():83-102. PubMed ID: 11791460 [No Abstract] [Full Text] [Related]
35. Tumour necrosis factor blockade in rheumatoid arthritis. Breedveld FC Clin Med (Lond); 2001; 1(2):107-9. PubMed ID: 11333452 [No Abstract] [Full Text] [Related]
36. [Anti-TNF-alpha monoclonal antibodies in the treatment of rheumatoid arthritis]. Mugnier B; Bouvenot G Rev Med Interne; 2000 Oct; 21(10):854-62. PubMed ID: 11075394 [TBL] [Abstract][Full Text] [Related]
37. Tumor necrosis factor-alpha blockade in the treatment of rheumatoid arthritis. Keystone EC Rheum Dis Clin North Am; 2001 May; 27(2):427-43. PubMed ID: 11396102 [TBL] [Abstract][Full Text] [Related]
38. Adalimumab (a fully human anti-tumour necrosis factor alpha monoclonal antibody) in the treatment of active rheumatoid arthritis: the initial results of five trials. Rau R Ann Rheum Dis; 2002 Nov; 61 Suppl 2(Suppl 2):ii70-3. PubMed ID: 12379628 [No Abstract] [Full Text] [Related]
39. Tumour necrosis factor-alpha blockers in rheumatoid arthritis: review of the clinical experience. Richard-Miceli C; Dougados M BioDrugs; 2001; 15(4):251-9. PubMed ID: 11437690 [TBL] [Abstract][Full Text] [Related]
40. Treatments no longer in development for rheumatoid arthritis. Keystone E Ann Rheum Dis; 2002 Nov; 61 Suppl 2(Suppl 2):ii43-5. PubMed ID: 12379620 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]